We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global POC Testing Market to Reach USD 30 Billion by 2022

By LabMedica International staff writers
Posted on 18 Sep 2019
The global Point-of-Care (POC) testing market is projected to reach USD 30 billion by 2022, driven by the immense potential of POC tests to improve global health and eventually reduce public and national spending on health.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

POC testing devices have now found applications in a large number of medical conditions and their increased usage in the field of critical care settings for delivering decentralized, patient-centric healthcare to patients is expected to drive a rapid growth in the POC testing market. Increasing awareness about POCT, technological advancements and increasing FDA approvals are the major drivers of the global POC testing market. However, some challenges, such as product recalls and lack of regulatory standards, are hindering market growth.

On the basis of type of product, glucose monitoring kits accounted for the largest market share in 2017 due to the rising prevalence of diabetes & technological advancements in self-monitoring of blood glucose. Based on geography, North America accounted for the largest share of the global POC testing market in 2017.

Related Links:
Research and Markets


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
POC Immunoassay Analyzer
Procise DX
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
18 Sep 2019  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
18 Sep 2019  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
18 Sep 2019  |   Industry



ADLM